Introduction
Hepatitis C virus (HCV) infection is one of the causes of chronic liver disease 1 . Chronic liver diseases increase liver fibrosis with structural and functional alterations as the amount of fibrosis is correlated with the risk of developing complication of cirrhosis and HCC 2 . Diagnosis and treatment of patients with chronic hepatitis mostly rely on the staging of liver fibrosis 3 . Liver biopsy is the standard procedure for staging fibrosis internationally 4,. 5 . On the contrary liver biopsy provides only a small part of the whole organ and this part might not be representative for the amount of hepatic fibrosis in the whole liver due to heterogeneity in its distribution 6 . By using liver stiffness measurement Transient elastography, the liver fibrosis can be staged using 1-dimensional ultrasound TE (FibroScan (R), Echosens, Paris, France) 7 . Advantages of TE include a short procedure time (<5 min), immediate results, and the ability to perform the test at the bedside or in an outpatient clinic. Finally, it is easy procedure can be performed by a nurse or a technician after minimal training (about 100 examinations) 8 . Numerous laboratory tests, and scores, have Summary Background and aims. Liver biopsy is the gold standard for diagnosis and staging of liver fibrosis, but it is invasive and has many complications that diminished its practice. Now, robust of non-invasive index for predicting fibrosis is very valuable. The aim of this study is to validate and determine the efficacy of noninvasive markers aspartate aminotransferase to platelet ratio (APRI), FIB4 and AFP versus Fibroscan for predicting the fibrosis stages of patients with chronic HCV infection. Methods: This crosssectional study included 621 patients with chronic hepatitis C infection attended out-patient clinic (Medical center Beni-Suef branch, the association of liver patient care, ELP, El-Mansoura) for HCV viral hepatitis treatment. The patients were diagnosed by RT-PCR. Sensitivity and specificity of APRI, FIb-4 and AFP were estimated by receiver operator characteristic curve (ROC) for predicting stage of fibrosis versus Fibroscan. Results: Compared to Fibroscan as standard at value 12 kPa, the sensitivity and specificity of APRI was (67% and 61% and AUC= 0.747), of FIb-4 was (77% and 72% and AUC = 0.769) and of AFP was (77% and 60% and AUC = 0.734) for predicting early stages of fibrosis (F0-F1-F2). However, with advanced liver fibrosis (F3-F4) compared to Fibroscan at value 15 kPa, the sensitivity and specificity of APRI was (100% and 95.3% and AUC= 0.960) and of FIb-4 was (100% and 87.4% and AUC= 0.879) and of AFP were (100% and 51% and AUC= 0.684) for predicting F4 fibrosis. Conclusion: Given the higher cost and reduced availability of Fibroscan, this study showed that, the non-invasive tests APRI,
FIB-4 index and AFP are practically useful markers for diagnosis and monitoring of liver fibrosis among patients with chronic HCV patients especially with advanced liver fibrosis.
Keywords: Liver stiffness measurement, Transient elastography, FibroScan, Liver fibrosis, Chronic Hepatitis C been proposed for non-invasive prediction of hepatic fibrosis in chronic HCV-infected patients. Amongst these, aspartate aminotransferase (AST)-to platelet ratio (APRI), and FIB4, are readily available in clinical practice with good accuracy for predicting hepatic fibrosis 9 . Elevated levels of AFP have been revealed to be more frequently associated with chronic liver disease and fibrosis and the value of measuring AFP in HCV has been called into question 10 . The aim of this study is to evaluate the efficacy of non-invasive markers APRI, FIB4 and AFP in comparison to Fibroscan for predicting the fibrosis stages of patients with chronic HCV infection.
Patients and Methods

Study design
This cross-sectional study was conducted at the HCV outpatient clinic (Medical center Beni-suef branch Egyptian liver Hospital, ELP, El-Mansoura) for HCV viral hepatitis treatment. The inclusion criteria were; age older than 18 years and chronic infection by hepatitis C diagnosed by RT-PCR. The exclusion criteria were the presence of ascites, pacemaker or pregnancy, co-infection with HBV or human immunodeficiency virus (HIV), other causes of chronic liver disease and patients with hepatocellular carcinoma. Laboratory assessment Routine laboratory assessment was done before the start of treatment including; complete blood picture, aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum albumin, serum bilirubin, prothrombin time (PT), and international normalization ratio (INR), serum creatinine, HBsAg, fasting blood sugar (FBS), Alfa fetoprotein (AFP). Serological analysis Quantitative HCV-RNA count. *The APRI score was calculated using Wai's formula (A) 11 . *The FIB4 score was calculated using Sterling's formula (B) 12 .
Abdominal Imaging
Abdominal and pelvic ultrasonography was done before treatment, to evaluate the signs of liver cirrhosis, hepatic decompensation, portal hypertension and fatty liver.
Transient elastography (TE)
The procedures were performed. The right lobe of the liver was accessed through an intercostal space while the patient was lying down in the dorsal decubitus position with the right arm in maximum abduction position. Using the FibroScan (Echosens 405, Paris, France), a portion of liver of at least 60 mm in thickness, free of large vessels, was identified for exam-ination. The rate of successful measurement was calculated as the ratio between the numbers of validated to total measurements. The results were expressed as a median value of the total measurements in kilo Pascal (kPa). TE was considered reliable when the following 3 criteria had been met: 10 successful measurements, an interquartile range (IQR) lower than 30% of the median value, and a success rate of more than 60% 13 . The cut-off values of the Fibroscan in hepatitis C virus mono-infection were meas-ured according to Ziolet al., 2005 14 :
Statistical analysis
Analysis of the data was done by IBM computer using SPSS (statistical package for social science version 22). Data were described as mean ± standard deviation (SD) for quantitative variables. One way ANOVA test was used for comparison of quantitative variable among more than two independent groups. Spearman correlation coefficient (r) test was used to rank different variables against each other either positive or inverse. The probability value (P) <0.05 was considered statistically significant. The receiver operator characteristic (ROC) curve was constructed to obtain the most sen-sitive and specific cut-off for each technique. Table 1 shows the clinical and demographic characteristics of the participants. The study included 621 patients, 349 males (40.1%) and 375 females (59.9%). Out of 621 patients incl-uded in this study, abdominal ultrasound was normal in 269 patients (43.3%), bright hepatomegaly was found in 177 patients (28.5%) and liver cirrhosis was found in 175 patients (28.2%) . Table 2 shows that, APRI in group A (F0-F1) stage of fibrosis was 0.32±0.22 that was increased at group D (F4) up to 1.01±0.93. While, FIB4 in group A of fibrosis was 0.99± 00.58 that was increased at advanced stage of fibrosis (group D) up to 2.44±1.7. Moreover, AFP level in group A stage of fibrosis was 3.7±3.1that was increased at advanced stage (group D) of fibrosis up to13.02±7.02. Table  3 shows the comparison between early (F0-F2) stages of fibrosis (12 kps) and advanced (F3-F4) stages of fibrosis (15 kps) measured by Fibroscan as regard the value of APRI, FIB 4 scores and AFP level. There was significant increase in APRI, FIB4 scores and AFP level at F3-F4 (advanced fibrosis) versus, early fibrosis (F0-F2). There was a statistically significant positive correlation between Fibroscan and patient criteria as regard, age, AFP, AST, ALT and portal vein diameter (P value was ≤ 0.001 for all) and significant negative correlation with serum albumin (p <0.001) and platelet (p= 0.002). Also there was a statically significant positive correlation between Fib-4 score and the age, AFP, AST, ALT (P value was ≤ 0.001 for all), creatinine (p= 0.004), portal vein diameter (p= 0.009) and WBC (p= 0.004), in addition there was a significant negative correlation with serum albumin and platelet (p <0.001). Furthermore, a statistically significant positive correlation was found betw-een APRI score and patient criteria included AFP, AST, ALT (p <0.001), portal vein diameter (p= 0.003) and significant negative correlation with serum albumin and platelet (p <0.001), tab. (4). Table 5 and figure 1 show the sensitivity, specificity and AUC of AFP, fib-4 and APRI at Fibroscan measurement at 12 kps for diagnosis of liver fibrosis stages. At a cut-off value of 3.97, the sensitivity and specificity of AFP was (77% and 60% respectively). Of FIB 4, at cut-off value of 1.36, the sensitivity and specificity of was (77% and 72% respectively). As regard the APRI at cutoff value of 0.33 the sensitivity and specificity of was (67% and 61% respectively) for diagnosis of fibrosis stages. Table 6 and figure 2 show the sensitivity, specificity and AUC of AFP, fib-4 and APRI at Fibro scan measurement at 15kps for diagnosis of liver fibrosis stages. At a cut-off value of 3.07, the sensitivity and specificity of AFP was (100 % and 51% respectively). Of FIB 4 at a cut-off value of 2.11, the sensitivity and specificity was (100 % and 87.4 % respectively). As regard the APRI, at cut-off value of 1.16 the sensitivity and specificity was (100% and 95.3% respectively) for diagnosis of fibrosis stages. 23 . In this study at fibroscan value 15 Kpas (F4), APRI score has shown higher specificity (95%) as compared to FIB4 (87%). This is in accordance with study that showed that, APRI has shown higher sensitivity (91.2%) as compared to FIB4 (73.6%) but had lowered specificity (32.4% vs 68.3%) 24 . In our study, the sex is not independently associated with HCV related hepatic fibrosis. A similar result was reported by Hishamet al 25 . In this study LSM by TE suggests that age, AST, ALT,AFP have a significant impact on fibrosis. A similar result was reported by Orasan et al 26 . In this study, when comparing APRI score and FIB4 score with different stage of fibrosis measured by fibroscan, we found, a statistically significant increase from early fibrosis stage (F1-F2) to advanced fibrosis stage (F3-F4), these results matched that of Sumida et al 23 . In our study we found a statistically significant positive correlation between Fibroscan and patient criteria as regard, age, AFP, AST, ALT and portal vein diameter and significant negative correlation with serum albumin and platelet. Also there was a statically significant positive correlation between Fib-4 score and the age, AFP, AST, ALT, creatinine, portal vein diameter, in addition a significant negative correlation with serum albumin and platelet. Furthermore, a statistically significant positive correlation was found between APRI score and patient criteria included AFP, AST, ALT, portal vein diameter and significant negative correlation with serum albumin and platelet. In the contrary, El Nakeeb 22 , found no statistically significant correlation as regard the gender, ALT, and apha fetoprotein. In this study platelet has negative correlation with fibroscan, Fib-4 and APRI score. Possible explanations for these correlations are Platelet count is known to correlate with the amount of portal hypertension and advanced fibrosis 27 . Portal vein diameter has statistically significant positive correlation with fibroscan, Fib-4 and APRI score. This was in agreement with study that compares and correlate FibroScan values with gray scale sonographic assessment of portal vein diameter and found variation of calibre of portal vein is a good indicator of moderate to severe fibrosis 28 . Our study shows a significant increase in APRI, FIB-4 and AFP levels with progression of fibrosis from mild fibrosis (F0-F1) stage to cirrhosis (F4) stage. This result was in agreement with the results of other study 24 .
Results
